Kiora Pharmaceuticals (KPRX) Net Income towards Common Stockholders (2014 - 2026)

Kiora Pharmaceuticals (KPRX) has reported Net Income towards Common Stockholders for 13 consecutive years, with -$2.1 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Net Income towards Common Stockholders rose 3.41% year-over-year to -$2.1 million; the trailing twelve-month figure through Jun 2026 stood at -$11.0 million (up 8.31% YoY), and the FY2025 full-year result was -$10.8 million, down 401.42% from the prior year.
• Net Income towards Common Stockholders advanced to -$2.1 million in Q2 2026 per KPRX's latest filing, from -$2.4 million in the prior quarter.
• Across five years, Net Income towards Common Stockholders topped out at $13.5 million in Q1 2024 and bottomed at -$12.2 million in Q3 2023.
• Historically, Net Income towards Common Stockholders has averaged -$2.9 million across 5 years, with a median of -$2.5 million in 2023.
• The sharpest annual moves came in 2022 and 2024: Net Income towards Common Stockholders slumped 190.73% in 2022, then surged 801.91% in 2024.
• Over 5 years, Net Income towards Common Stockholders stood at -$5.1 million in 2022, then gained by 15.48% to -$4.3 million in 2023, then rose by 2.72% to -$4.2 million in 2024, then slumped by 54.29% to -$6.5 million in 2025, then jumped by 68.1% to -$2.1 million in 2026.
• According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered -$2.1 million, -$2.4 million, and -$6.5 million for Q2 2026, Q1 2026, and Q4 2025 respectively.